Companies Tempus AI

Tempus AI

Chicago

Total Offices: 11

3,775 Total Employees

Year Founded: 2015

View Website

We're Hiring!

Data & Analytics 5 Sales 5 AI & Machine Learning 4 Engineering 4 Product Management 4 Finance 3 Operations & Support 3 Customer Success & Experience 2 Program & Project Management 2 Consulting 1 Cybersecurity 1 Design 1 HR & Recruiting 1 Marketing 1 Supply Chain & Procurement 1

View all jobs

Tempus AI Company Growth, Stability & Outlook in Chicago

Updated on September 16, 2026

What's the stability & growth outlook for Tempus AI?

The Chicago office is characterized by a high‑growth, partnership‑rich environment supported by accelerating revenue, expanding diagnostics volumes, and momentum in data licensing and regulatory progress. Together, these dynamics suggest the Chicago location offers strong business stability with improving profitability signals and clear visibility from marquee collaborations.

Key Insight for Candidates

Measurable, sustained momentum—repeated guidance raises, accelerating oncology volumes, major data‑license wins, FDA approvals, and a first GAAP‑profitable quarter—defines Tempus. In Chicago, employees operate amid frequent, visible wins that reinforce stability and growth, as expanding diagnostics and data programs create tangible impact across teams.

Evidence in Action

Quarterly Guidance Updates — 2026 revenue guidance was raised to $1.59–$1.60B (Q1 2026) and nudged to $1.595–$1.605B (Q2 2026). Chicago teams gain clear growth visibility to plan staffing, prioritize initiatives, and align goals with updated expectations.
Transparent Volume Reporting — Oncology test volume grew 29% YoY in Q4 2025, 28% in Q1 2026, and 31% in Q2 2026. Consistent metric sharing lets Chicago employees track momentum, calibrate targets, and communicate progress with confidence.

Positive Themes About Tempus AI

Strong Revenue Growth: The Chicago team operates within a company posting rapid top-line expansion, with revenue up sharply in 2025 and continuing double‑digit growth into 2026 alongside raised full‑year guidance. Diagnostics volumes and the data‑licensing business are both scaling, reinforcing the trajectory.
Strategic Partnerships: High‑profile, multi‑year collaborations with leading biopharma and health systems signal durable demand for the platform. New and expanded agreements, along with substantial new data‑licensing signings, strengthen pipeline visibility for teams on the ground.
Profitability: The organization reached its first GAAP‑profitable quarter in 2026 and showed improving adjusted EBITDA trends, indicating progress toward sustained profitability. This financial momentum provides added operating stability locally.